253 related articles for article (PubMed ID: 23818211)
21. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
22. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy.
Ebbinghaus C; Ronca R; Kaspar M; Grabulovski D; Berndt A; Kosmehl H; Zardi L; Neri D
Int J Cancer; 2005 Aug; 116(2):304-13. PubMed ID: 15800913
[TBL] [Abstract][Full Text] [Related]
23. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.
Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M
Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083
[TBL] [Abstract][Full Text] [Related]
24. Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.
Stringhini M; Mock J; Fontana V; Murer P; Neri D
MAbs; 2021; 13(1):1868066. PubMed ID: 33404287
[TBL] [Abstract][Full Text] [Related]
25. Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.
Mendiratta SK; Quezada A; Matar M; Thull NM; Bishop JS; Nordstrom JL; Pericle F
Hum Gene Ther; 2000 Sep; 11(13):1851-62. PubMed ID: 10986558
[TBL] [Abstract][Full Text] [Related]
26. An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties.
Gafner V; Trachsel E; Neri D
Int J Cancer; 2006 Nov; 119(9):2205-12. PubMed ID: 16823838
[TBL] [Abstract][Full Text] [Related]
27. Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities.
Dreier T; Lode HN; Xiang R; Dolman CS; Reisfeld RA; Kang AS
Bioconjug Chem; 1998; 9(4):482-9. PubMed ID: 9667950
[TBL] [Abstract][Full Text] [Related]
28. Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.
Börschel N; Schwöppe C; Zerbst C; Angenendt L; Kessler T; Klapper W; Giovannoni L; Elia G; Neri D; Berdel WE; Mesters RM; Schliemann C
Leuk Res; 2015 Jul; 39(7):739-48. PubMed ID: 25934049
[TBL] [Abstract][Full Text] [Related]
29. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.
Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D
Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369
[TBL] [Abstract][Full Text] [Related]
30. Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.
Schmid AS; Tintor D; Neri D
J Biotechnol; 2018 Apr; 271():29-36. PubMed ID: 29438784
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.
Andrews KJ; Ribas A; Butterfield LH; Vollmer CM; Eilber FC; Dissette VB; Nelson SD; Shintaku P; Mekhoubad S; Nakayama T; Taniguchi M; Glaspy JA; McBride WH; Economou JS
Cancer Res; 2000 Nov; 60(22):6457-64. PubMed ID: 11103813
[TBL] [Abstract][Full Text] [Related]
32. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2.
Schliemann C; Palumbo A; Zuberbühler K; Villa A; Kaspar M; Trachsel E; Klapper W; Menssen HD; Neri D
Blood; 2009 Mar; 113(10):2275-83. PubMed ID: 19005180
[TBL] [Abstract][Full Text] [Related]
33. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy.
Mårlind J; Kaspar M; Trachsel E; Sommavilla R; Hindle S; Bacci C; Giovannoni L; Neri D
Clin Cancer Res; 2008 Oct; 14(20):6515-24. PubMed ID: 18927291
[TBL] [Abstract][Full Text] [Related]
34. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
[TBL] [Abstract][Full Text] [Related]
35. The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate.
Pasche N; Frey K; Neri D
Angiogenesis; 2012 Mar; 15(1):165-9. PubMed ID: 22052195
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-4 and CpG oligonucleotide therapy suppresses the outgrowth of tumors by activating tumor-specific Th1-type immune responses.
Kajiwara A; Doi H; Eguchi J; Ishii S; Hiraide-Sasagawa A; Sakaki M; Omori R; Hiroishi K; Imawari M
Oncol Rep; 2012 Jun; 27(6):1765-71. PubMed ID: 22426807
[TBL] [Abstract][Full Text] [Related]
37. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
38. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
39. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.
Adams S; Miller GT; Jesson MI; Watanabe T; Jones B; Wallner BP
Cancer Res; 2004 Aug; 64(15):5471-80. PubMed ID: 15289357
[TBL] [Abstract][Full Text] [Related]
40. Gene transfer of NK4, an angiogenesis inhibitor, induces CT26 tumor regression via tumor-specific T lymphocyte activation.
Kubota T; Taiyoh H; Matsumura A; Murayama Y; Ichikawa D; Okamoto K; Fujiwara H; Ikoma H; Nakanishi M; Kikuchi S; Ochiai T; Sakakura C; Kokuba Y; Sonoyama T; Suzuki Y; Matsumoto K; Nakamura T; Otsuji E
Int J Cancer; 2009 Dec; 125(12):2879-86. PubMed ID: 19588506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]